Company intelligence / Profile preview

Rigenerand

Medolla, Emilia-Romagna, Italyrigenerand-biotech.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Rigenerand developed cGMP-compliant products and platforms supporting the development of advanced cell and gene therapies as well as innovative biomedical devices. The company enabled preclinical to early clinical-stage programs in regenerative medicine, oncology, immunotherapy, and diagnostics through its manufacturing capabilities. No direct late-stage or commercial therapeutics reported.

Therapeutic areas: OtherOncology
Modalities: Cell therapyGene therapy3D culture biomedical devices (Device)Stem cell therapy
Industry: Contract Manufacturing Organization

Drug pipeline

1 asset

RR001

Phase 1

Indications: Pancreatic ductal adenocarcinoma

Partnerships

RanD Srl (joint venture partner)University of Modena e Reggio Emilia (academic founding partner)Evotec SE (acquirer/investor)

Beyond the preview

Go deeper on Rigenerand.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rigenerand.

Explore the full profile